SynthesisFrontiers in pharmacology2025
Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Electrosprayed PLGA Nanoparticles for Dual Drug Delivery: Design, Optimization and Applications.Polymers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer treatment remains a major challenge to modern medicine and has driven the need for nanotechnology-based strategies to improve drug delivery and overcome chemoresistance. Poly(ethylene glycol) and poly (lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs) are a type of FDA-approved biodegradable copolymer (lactic + glycolic acids) that degrades into non-toxic metabolites (lactic acid and glycolic acid); it has emerged as a promising drug carrier owing to its biocompatibility, sustained release properties, and ability to enhance the cellular uptake of chemotherapeutic agents. This systematic review examines the efficacies of PEG-PLGA nanoparticles loaded with antineoplastic drugs on Methods: Following PRISMA guidelines, we conducted a comprehensive search of the Web of Science, Embase, MEDLINE, and Scopus databases to identify experimental studies published between 2014 and August 2025 that evaluated PEG-PLGA formulations applied to breast cancer cell lines. The methodological quality of each study was appraised using the National Institute for Health and Care Excellence (NICE) criteria. Results: Thirteen studies were chosen based on our inclusion criteria. Here, the PEG-PLGA nanoparticles were predominantly spherical (30-210 nm) and exhibited controlled release kinetics. Compared with free drugs, the nanoformulations significantly reduced cell viability, increased apoptosis, and induced cell-cycle arrest. Functionalization with ligands such as folic acid enhanced drug targeting and cytotoxicity, while the molecular analyses revealed upregulation of p53, Bax, and caspases as well as downregulation of Conclusion: PEG-PLGA nanoparticles can substantially improve the selectivity, bioavailability, and cytotoxic efficacies of anticancer drugs in breast cancer Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251076570.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.